PubMed
Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial)
Davalos A, Alvarez-Sabin J, Castillo J, et al. Lancet. 2012
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 52% · Mixed 36% · Unfavorable overall 12%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.2–0.4 mg · Most common: 0.1–0.2 mg
Reports span 0.01–2 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 62% said they felt similar to their last entry, 32% more positive, and 12% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 15 days · Based on 46 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 70% · Mixed 18% · Unfavorable overall 12%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 100–200 mcg · Most common: 100–200 mcg
Reports span 10–1000 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 65% said they felt similar to their last entry, 32% more positive, and 20% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 24 days · Based on 83 repeat reporters
Published sources linked on the CDP-Choline and RU-58841 wiki pages.
PubMed
Davalos A, Alvarez-Sabin J, Castillo J, et al. Lancet. 2012
PubMed
Zafonte RD, Bagiella E, Ansel BM, et al. JAMA. 2012
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2006
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2007
PubMed
Miyamoto H, Yeh S, Lardy H, et al. J Steroid Biochem Mol Biol. 1997
PubMed
Pan HJ, Wilding G, Uno H, et al. Endocrine. 1998
PubMed
Ye F, Imamura K, Imanishi N, et al. Skin pharmacology : the official journal of the Skin Pharmacology Society. 1997